Researchers have developed a novel compound, FLAV-27, that targets the G9a enzyme to therapeutically reprogram the epigenome of neurons, offering a new strategy for Alzheimer's treatment by addressing upstream gene expression changes rather than solely focusing on amyloid-beta plaques. This approach has shown promising results in cell experiments, nematodes, and mice, where it restored brain cell function, improved memory performance, social behavior, and synapse function, and even reduced amyloid-beta plaques and tau tangles. Unlike current treatments that slow progression, FLAV-27 aims to reverse cognitive decline by targeting the underlying molecular mechanisms of the disease, though it still requires extensive testing before human trials can begin.